Price
$2.7
Decreased by -4.93%
Dollar Volume
38.18 K
ADR%
8.61
Earnings Report Date (estimate)
Feb 22, 23 (-0.33)
Market Cap.
18.92 M
Shares Float
5.16 M
Shares Outstanding
7.01 M
Beta
1.36
Price / Earnings
-2.79
BPR
14.09
20D Range
2.43 3.36
50D Range
2.03 4.24
200D Range
2.03 7.92
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.75
Decreased by -25.00%
-0.40
Decreased by -87.50%
Jul 27, 22 -0.45
Decreased by -143.69%
-0.55
Increased by +18.18%
May 9, 22 -0.85
Decreased by -34.92%
-0.69
Decreased by -23.19%
Feb 24, 22 -0.59
Decreased by -227.78%
-0.42
Decreased by -40.48%
Oct 28, 21 -0.60
Decreased by -400.00%
-0.52
Decreased by -15.38%
Aug 13, 21 1.03
Increased by +301.96%
1.06
Decreased by -2.83%
Apr 28, 21 -0.63
Decreased by -162.50%
-0.54
Decreased by -16.67%
Feb 24, 21 -0.18
Decreased by -325.00%
-0.04
Decreased by -350.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 13.60 M
Increased by +11.89%
-5.26 M
Decreased by -25.68%
Decreased by -38.66%
Decreased by -12.32%
Jun 30, 22 14.60 M
Decreased by -32.71%
-3.12 M
Decreased by -141.18%
Decreased by -21.33%
Decreased by -161.19%
Mar 31, 22 11.90 M
Increased by +6.10%
-5.96 M
Decreased by -63.24%
Decreased by -50.05%
Decreased by -53.86%
Dec 31, 21 13.96 M
Increased by +1.34%
-4.11 M
Decreased by -320.27%
Decreased by -29.41%
Decreased by -314.70%
Sep 30, 21 12.15 M
Decreased by -2.57%
-4.18 M
Decreased by -576.86%
Decreased by -34.42%
Decreased by -594.68%
Jun 30, 21 21.70 M
Increased by +116.21%
7.57 M
Increased by +397.13%
Increased by +34.86%
Increased by +237.43%
Mar 31, 21 11.21 M
Decreased by -22.85%
-3.65 M
Decreased by -204.51%
Decreased by -32.53%
Decreased by -294.69%
Dec 31, 20 13.77 M
Decreased by -20.60%
-977.00 K
Decreased by -296.18%
Decreased by -7.09%
Decreased by -347.09%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.